| Literature DB >> 23881345 |
Paweł Dębiński1, Janusz Dembowski, Paweł Kowal, Tomasz Szydełko, Anna Kołodziej, Bartosz Małkiewicz, Krzysztof Tupikowski, Romuald Zdrojowy.
Abstract
BACKGROUND: The formation of lymphatic vessels (lymphangiogenesis) occurs in tumor tissues and is crucial for tumor development and progression in some cancers. Lymphangiogenesis and its clinical effect on renal cell carcinoma have been less thoroughly investigated in comparison with angiogenesis. The aim of this study was to evaluate the role of lymphangiogenesis as a prognostic factor in renal cell carcinoma (RCC).Entities:
Mesh:
Year: 2013 PMID: 23881345 PMCID: PMC3724570 DOI: 10.12659/MSM.883981
Source DB: PubMed Journal: Med Sci Monit ISSN: 1234-1010
Patient characteristics.
| Group I | Group II | Group III | All | |
|---|---|---|---|---|
| Sex n (%) | ||||
| Male | 40 (57) | 15 (80) | 27 (75) | 82 (62) |
| Female | 37 (43) | 5 (20) | 9 (25) | 51 (38) |
|
| ||||
| Follow up period months (range) | 82.7 (12–156) | 55 (13–140) | 25.4 (1–146) | 63.3 (0.5–156) |
|
| ||||
| Mean age (years) | 61.3 | 62.7 | 65.2 | 62.4 |
|
| ||||
| Side n (%) | ||||
| Right | 41 (53) | 8 (40) | 20 (56) | 69 (52) |
| Left | 36 (47) | 12 (60) | 16 (44) | 64 (48) |
|
| ||||
| Grade n (%) | ||||
| G1 | 19 (25) | 1 (5) | 1 (3) | 21 (16) |
| G2 | 44 (57) | 11 (55) | 12 (33) | 67 (50) |
| G3 | 13 (17) | 7 (35) | 18 (50) | 38 (29) |
| G4 | 1 (1) | 1 (5) | 5 (14) | 7 (5) |
|
| ||||
| T path. stage n (%) | ||||
| T1a | 14 (18) | 3 (15) | 0 (0) | 17 (13) |
| T1b | 31 (41) | 5 (25) | 5 (14) | 41 (31) |
| T2 | 11 (14) | 3 (15) | 3 (8) | 17 (13) |
| T3a | 15 (20) | 6 (30) | 11 (31) | 32 (24) |
| T3b | 5 (6) | 1 (5) | 9 (25) | 15 (11) |
| T4 | 1 (1) | 2 (10) | 8 (22) | 11 (8) |
|
| ||||
| Mean maximal tumor diameter cm | 6.0 | 6.7 | 8.4 | 6.7 |
Figure 1Immunostaining with antibody D2-40 revealed intratumoral lymphatic vessels (ITL) in clear cell renal cell carcinoma (magnification 100×).
Figure 2Immunostaining with antibody D2-40 revealed peritumoral lymphatic vessels (PTL) in clear cell renal cell carcinoma (magnification 100×).
Figure 3Cancer specific survival rates according to presence of ITL(p=0.003).
Figure 4Cancer specific survival rates according to mean number of ITL (p=0.00003).
Figure 5Cancer specific survival rates according to mean number of PTL (p=0.032).